Table 3. Clinical outcomes of commonly used second-line anticancer agents as compared with γδ T-cell immunotherapy.*.
Disease | Second-line treatments | CR | PR | SD | PD | ||||
---|---|---|---|---|---|---|---|---|---|
% | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | ||
Advanced prostate cancer48 | Prednisolone + docetaxel (n = 101, 3 randomized controlled trials) | 0 | 0 | 25.2 | 8.4–41.8 | 44.43 | 32–56.8 | 30.40 | 14.5–46.2 |
In-vivo expansion of γδT cells (n = 12, 6 missing) | 0 | 33.3 | 41.6 | 25.0 | |||||
Advanced renal cell carcinoma52 | Everolimus (n = 277, 1 randomized phase 3 study) | 0 | 0 | 1.8 | - | 66.5 | - | 31.7 | - |
Adoptive transfer of γδT cells (n = 21, 7 missing) | 4.8 | 0 | 0 | 42.9 | 52.4 | ||||
In-vivo expansion of γδT cells (n = 15, 4 missing) | 0 | 0 | 0 | 0 | 66.7 | 33.3 | |||
Advanced NSCLC53,54 | Erlotinib (n = 3324, 2 randomized controlled trials) | 0.4 | 0.17–0.73 | 7.2 | 1.88–10.89 | 33.9 | 4.9–43.4 | 58.5 | 6.9–72.1 |
Docetaxel (n = 385, 2 randomized controlled trials) | 2.6 | 0.3–4.9 | 9.6 | 8.9–10.2 | 37.7 | 30.0–45.3 | 50.2 | 45.5–55.0 | |
Adoptive transfer of γδT cells (n = 24, 1 missing) | 0 | 0 | 54.2 | 45.8 |
Data are pooled from clinical trials and standard of care treatments were selected based upon current UK or US guidelines for treatment of the tumors in question. A more detailed breakdown of γδT cell immunotherapy results is included in Table S2. CI, confidence interval; CR, complete response; NSCLC, non-small cell lung carcinoma; PD, progressive disease; PR, partial response; SD, stable disease.